Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
(American Society for Radiation Oncology) Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study published in the January 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics, the official scientific journal of the American Society for Radiation Oncology.
ConclusionComplete absence of nodes assessed was associated with worse prognosis compared to node-negative and node-positive patients. In node-negative patients number of nodes was not associated to OS and CIDD. Based on data from this large population of irradiated RC, number of nodes assessed has no prognostic impact in node-negative patients.
Publication date: July 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 7Author(s): A.J.M. Rombouts, N. Hugen, R.H.A. Verhoeven, M.A.G. Elferink, P.M.P. Poortmans, I.D. Nagtegaal, J.H.W. de WiltAbstractBackgroundIn the era of organ preserving strategies in rectal cancer, insight into the efficacy of preoperative therapies is crucial. The goal of the current study was to evaluate and compare tumor response in rectal cancer patients according to their type of preoperative therapy.MethodsAll rectal cancer patients diagnosed between 2005 and 2014, receiving radiation therapy (RT, 5 × 5Gy; N&n...
AbstractPurpose of ReviewFor patients with locally advanced rectal cancer, neoadjuvant hypofractionated short-course radiation remains an underutilized regimen in the USA. We review the current clinical literature highlighting the relative merits of short-course radiation, along with modern neoadjuvant strategies that incorporate its use.Recent FindingsAs compared to long-course chemoradiation with delayed surgery, short-course radiation with early surgery offers similar oncologic efficacy for locally advanced rectal cancer patients. Delaying surgery after short-course radiation decreases post-operative complications as co...
The present study aimed to identify a panel of potential metabolite biomarkers to predict tumor response to neoadjuvant chemo-radiation therapy (NCRT) in locally advanced rectal cancer (LARC).
We report a case of bleeding ileal varices associated with intra-abdominal adhesions after colectomy which was successfully diagnosed using capsule endoscopy. A 77-year-old woman visited the emergency department for several episodes of melena. She had a medical history of neoadjuvant chemo-radiation therapy and subsequent surgery for rectal cancer 6 years previously. Conventional diagnostic examinations including upper endoscopy, colonoscopy, and abdominal computed tomography could not detect any bleeding focus, however, following capsule endoscopy revealed venous dilatations with some fresh blood in the distal ileum, indi...
In this edition of the GI Oncology Scan, we would like to express our deepest gratitude to Daniel Chang, MD, who has served as the Senior Editor for the GI Red Journal Editorial Team for the past 4 years and recently retired from this role. As a leader in the field of gastrointestinal (GI) oncology, Dan is a highly accomplished radiation oncologist who has headed the efforts in developing stereotactic body radiation therapy (RT) for pancreatic cancer and innovative concepts in GI radiation o ncology.
Introduction: Radiotherapy (RT) and surgery are known to effectively palliate many symptoms of patients with metastatic rectal cancer (mRC). However, whether RT would provide survival benefit to mRC after surgery remains unclear.
Introduction: Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and downstage.
Conclusions Despite a more advanced clinical stage, complete pathologic response was more common in patients treated with CRT than in patients treated with RT. Prospective trials are needed to establish the differences in other outcome parameters, including the impact on organ preserving strategies.
Approximately 50% of all cancer patients undergo radiation therapy (RT) as part of their primary treatment regimen. During RT, high dosages of ionizing radiation are delivered which generate oxygen-derived free radicals. These radicals induce DNA damage and eventually cause apoptosis.[2,3] The addition of RT to a treatment regimen is generally associated with a reduction in recurrences and improvement of prognosis in many types of cancer.[4 –8] However, RT is also known to cause acute and late toxicity.